Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Colorectal Neoplasms

Free Subscription 08.04.2024 1 Ann Oncol 2 BMC Cancer 1 BMC Gastroenterol 2 Br J Cancer 2 Cancer Lett 1 Clin Cancer Res 1 Discov Oncol 5 Eur J Surg Oncol 3 Gastroenterology 4 Int J Cancer 3 Int J Colorectal Dis 1 J Clin Oncol 1 J Natl Cancer Inst 1 J Pathol 4 J Surg Oncol 2 Lancet Oncol 1 Oncogene 1 Oncol Rep 4 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Oncol

1. KELSEN D, Ben-Aharon I, Gordon N
   Identifying Genetic Loci Associated with an Increased Risk for Early Onset Colorectal Cancer.
   Ann Oncol. 2024 Apr 3:S0923-7534(24)00106-6. doi: 10.1016/j.annonc.2024.
   PubMed        
   
   

   
   BMC Cancer

2. LEE KH, Yang IJ, Ha GW, Lee J, et al
   mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial.
   BMC Cancer. 2024;24:397.
   PubMed         Abstract available
   
   
3. GHOFRANI-SHAHPAR M, Pakravan K, Razmara E, Amooie F, et al
   Cancer-associated fibroblasts drive colorectal cancer cell progression through exosomal miR-20a-5p-mediated targeting of PTEN and stimulating interleukin-6 production.
   BMC Cancer. 2024;24:400.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

4. MATSUBARA D, Soga K, Ikeda J, Kumano T, et al
   Impact of severe postoperative complications on the prognosis of older patients with colorectal cancer: a two-center retrospective study.
   BMC Gastroenterol. 2024;24:125.
   PubMed         Abstract available
   
   

   
   Br J Cancer

5. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
   Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
   Br J Cancer. 2024 Apr 4. doi: 10.1038/s41416-024-02667.
   PubMed        
   
   
6. TIAN Y, Lin Y, Qu C, Arndt V, et al
   Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
   Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638.
   PubMed         Abstract available
   
   

   
   Cancer Lett

7. JIANG C, Zhou Q, Yi K, Yuan Y, et al
   Colorectal cancer initiation: Understanding early-stage disease for intervention.
   Cancer Lett. 2024 Apr 2:216831. doi: 10.1016/j.canlet.2024.216831.
   PubMed         Abstract available
   
   
8. ZHOU Y, Li H, Zhang Y, Zhao E, et al
   Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer.
   Cancer Lett. 2024 Mar 29:216836. doi: 10.1016/j.canlet.2024.216836.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

9. MOUILLET-RICHARD S, Cazelles A, Sroussi M, Gallois C, et al
   Clinical challenges of consensus molecular subtype CMS4 colon cancer in the era of precision medicine.
   Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-3964.
   PubMed         Abstract available
   
   

   
   Discov Oncol

10. GUAN X, Cui L, Ruan Y, Fang L, et al
    Heterogeneous expression of ARID1A in colorectal cancer indicates distinguish immune landscape and efficacy of immunotherapy.
    Discov Oncol. 2024;15:92.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

11. CAI Y, Chen M, Ye F, Liu Z, et al
    The clinical relevance of adjuvant chemotherapy in locally advanced rectal cancer patients achieving near pathological complete response following neoadjuvant chemoradiotherapy: Insights from ypT stage.
    Eur J Surg Oncol. 2024;50:108001.
    PubMed         Abstract available
    
    
12. KNITTER S, Raschzok N, Hillebrandt KH, Benzing C, et al
    Short-term postoperative outcomes of lymphadenectomy for cholangiocarcinoma, hepatocellular carcinoma and colorectal liver metastases in the modern era of liver surgery: Insights from the StuDoQ|Liver registry.
    Eur J Surg Oncol. 2024;50:108010.
    PubMed         Abstract available
    
    
13. QIAN C, Yang W, Li M, Feng Y, et al
    Negative prognostic impact of Co-mutations in TGFbeta and TP53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy.
    Eur J Surg Oncol. 2024;50:108242.
    PubMed         Abstract available
    
    
14. NUIJENS BW, Lindeboom R, van den Broek JJ, Geenen RWF, et al
    A prediction model for lung metastases in patients with indeterminate pulmonary nodules in newly diagnosed colorectal cancer.
    Eur J Surg Oncol. 2024;50:108305.
    PubMed         Abstract available
    
    
15. MALIK HZ, Siriwardena AK
    Towards standardized terminology for patients with synchronous colorectal cancer and liver metastases.
    Eur J Surg Oncol. 2024;50:108315.
    PubMed        
    
    

    
    Gastroenterology

16. WEINBERG DS, Barkun A
    Liquid Biopsy for Colorectal Cancer Screening: Not So Bloody Fast.
    Gastroenterology. 2024 Mar 25:S0016-5085(24)00305.
    PubMed        
    
    
17. VAN DEN PUTTELAAR R, Nascimento de Lima P, Knudsen AB, Rutter CM, et al
    Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services Coverage Decision.
    Gastroenterology. 2024 Mar 18:S0016-5085(24)00174.
    PubMed         Abstract available
    
    
18. LADABAUM U, Mannalithara A, Weng Y, Schoen RE, et al
    Comparative Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With Blood-Based Biomarkers (Liquid Biopsy) vs Fecal Tests or Colonoscopy.
    Gastroenterology. 2024 Mar 21:S0016-5085(24)00293.
    PubMed         Abstract available
    
    

    
    Int J Cancer

19. LI YJ, Wang X, Wu YJ, Zhou XY, et al
    Access to colorectal cancer screening in populations in China, 2020: A coverage-focused synthesis analysis.
    Int J Cancer. 2024 Mar 30. doi: 10.1002/ijc.34938.
    PubMed         Abstract available
    
    
20. BRENNER H, Weber L, Cardoso R, Heisser T, et al
    Indications of sustained delay of colorectal cancer diagnoses in Germany during the first 2 years of the COVID-19 pandemic.
    Int J Cancer. 2024 Apr 1. doi: 10.1002/ijc.34943.
    PubMed        
    
    
21. MOEN L, Liu B, Bukirwa P, Chingonzoh T, et al
    Trends in the incidence of colorectal cancer in sub-Saharan Africa: A population-based registry study.
    Int J Cancer. 2024 Apr 3. doi: 10.1002/ijc.34942.
    PubMed         Abstract available
    
    
22. BOUVIER AM, Jooste V, Lillini R, Marcos-Gragera R, et al
    Differences in survival and recurrence of colorectal cancer by stage across population-based European registries.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34944.
    PubMed         Abstract available
    
    

    
    Int J Colorectal Dis

23. WANG K, He H, Lin Y, Zhang Y, et al
    A new clinical model for predicting lymph node metastasis in T1 colorectal cancer.
    Int J Colorectal Dis. 2024;39:46.
    PubMed         Abstract available
    
    
24. XIA S, Zhu Y, Luo L, Wu W, et al
    Prognostic value of depression and anxiety on colorectal cancer-related mortality: a systematic review and meta-analysis based on univariate and multivariate data.
    Int J Colorectal Dis. 2024;39:45.
    PubMed         Abstract available
    
    
25. YU W, Xu B, Li P
    A novel log odds of positive lymph nodes-based nomogram for predicting overall survival in patients with colorectal signet ring cell carcinoma: a SEER population-based study.
    Int J Colorectal Dis. 2024;39:44.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

26. HU H, Zhang J, Li Y, Wang X, et al
    Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial.
    J Clin Oncol. 2024 Apr 2:JCO2301889. doi: 10.1200/JCO.23.01889.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

27. FANG A, Ugai T, Gurjao C, Zhong R, et al
    Alcohol and colorectal cancer risk subclassified by mutational signatures of DNA mismatch repair deficiency.
    J Natl Cancer Inst. 2024 Apr 4:djae078. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Pathol

28. MAKINO K, Ishii T, Takeda H, Saito Y, et al
    Integrated analyses of the genetic and clinicopathological features of cholangiolocarcinoma: cholangiolocarcinoma may be characterized by mismatch-repair deficiency.
    J Pathol. 2024;263:32-46.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

29. ALI D, Syed M, Gamboa AC, Hawkins AT, et al
    Association of omental pedicled flap with anastomotic leak following low anterior resection for rectal cancer.
    J Surg Oncol. 2024;129:930-938.
    PubMed         Abstract available
    
    
30. WEHRLE CJ, Woo K, Chang J, Gamaleldin M, et al
    Impact of neoadjuvant therapy on nodal harvest in clinical stage III rectal cancer: Establishing optimum cut-offs by disease response.
    J Surg Oncol. 2024;129:945-952.
    PubMed         Abstract available
    
    
31. STEVANATO FILHO PR, Bezerra TS, Marques TMDM, Nahime RH, et al
    A precise approach to robotic intracorporeal rectal transection and hand-sewn purse-string anastomosis for low anterior resection.
    J Surg Oncol. 2024;129:939-944.
    PubMed         Abstract available
    
    
32. BEPPU T, Yamamura K, Imai K, Hayashi H, et al
    Recurrence-risk stratification using the Beppu score and selection of perioperative chemotherapy for colorectal liver metastases.
    J Surg Oncol. 2024;129:893-900.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

33. MARTINELLI E, Ciardiello D
    Combining chemotherapy and immunotherapy for advanced anal cancer: are we ready?
    Lancet Oncol. 2024;25:416-417.
    PubMed        
    
    
34. KIM S, Ghiringhelli F, de la Fouchardiere C, Evesque L, et al
    Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
    Lancet Oncol. 2024;25:518-528.
    PubMed         Abstract available
    
    

    
    Oncogene

35. WU Q, Wang Z, Chen S, She X, et al
    USP26 promotes colorectal cancer tumorigenesis by restraining PRKN-mediated mitophagy.
    Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03009.
    PubMed         Abstract available
    
    

    
    Oncol Rep

36. ZHANG X, He L, Li Y, Qiu Y, et al
    Compound 225# inhibits the proliferation of human colorectal cancer cells by promoting cell cycle arrest and apoptosis induction.
    Oncol Rep. 2024;51:70.
    PubMed         Abstract available
    
    

    
    PLoS One

37. OKUNO K, Ikemura K, Okamoto R, Oki K, et al
    CAF-associated genes putatively representing distinct prognosis by in silico landscape of stromal components of colon cancer.
    PLoS One. 2024;19:e0299827.
    PubMed         Abstract available
    
    
38. WORTHINGTON J, Sun Z, Fu R, Lew JB, et al
    COVID-related disruptions to colorectal cancer screening, diagnosis, and treatment could increase cancer Burden in Australia and Canada: A modelling study.
    PLoS One. 2024;19:e0296945.
    PubMed         Abstract available
    
    
39. LIANG Y, Zhang X, Li S, Wang Z, et al
    Comparison of psychological interventions for anxiety, depression, fatigue and quality of life in colorectal cancer survivors: A systematic review and network meta-analysis protocol.
    PLoS One. 2024;19:e0298589.
    PubMed         Abstract available
    
    
40. PUSPITANINGTYAS H, Hutajulu SH, Fachiroh J, Anggorowati N, et al
    Diverging likelihood of colon and rectal cancer in Yogyakarta, Indonesia: A cross sectional study.
    PLoS One. 2024;19:e0301191.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.